Catawba Capital Management’s GSK GSK Stock Holding History

Catawba Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$572K	Hold	11,356	–	–	0.13%	123
2018 Q1	$555K	Buy	11,356 +648	+6%	+$30.2K	0.13%	124
2017 Q4	$475K	Sell	10,708 -5,740	-35%	-$265K	0.11%	137
2017 Q3	$835K	Buy	16,448 +250	+2%	+$12.7K	0.19%	103
2017 Q2	$873K	Buy	16,198 +1,280	+9%	+$68.2K	0.2%	106
2017 Q1	$786K	Sell	14,918 -398	-3%	-$20.2K	0.17%	121
2016 Q4	$737K	Sell	15,316 -580	-4%	-$28.7K	0.17%	125
2016 Q3	$857K	Buy	15,896 +704	+5%	+$38.6K	0.2%	110
2016 Q2	$823K	Hold	15,192	–	–	0.2%	111
2016 Q1	$770K	Sell	15,192 -2,140	-12%	-$107K	0.2%	109
2015 Q4	$874K	Sell	17,332 -1,512	-8%	-$77.1K	0.24%	99
2015 Q3	$906K	Buy	18,844 +456	+2%	+$23.7K	0.25%	95
2015 Q2	$957K	Hold	18,388	–	–	0.23%	101
2015 Q1	$1.06M	Buy	18,388 +384	+2%	+$22K	0.24%	96
2014 Q4	$962K	Buy	18,004 +168	+0.9%	+$9.4K	0.22%	99
2014 Q3	$1.02M	Hold	17,836	–	–	0.24%	94
2014 Q2	$1.19M	Buy	17,836 +396	+2%	+$26.8K	0.27%	93
2014 Q1	$1.17M	Sell	17,440 -348	-2%	-$23.5K	0.28%	90
2013 Q4	$1.19M	Buy	17,788 +2,100	+13%	+$136K	0.28%	89
2013 Q3	$984K	Buy	15,688 +72	+0.5%	+$4.63K	0.26%	90
2013 Q2	$975K	Buy	+15,616	New	+$991K	0.27%	88

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Catawba Capital Management's GSK Position: Q2 2018 in Review

Catawba Capital Management held its GSK (GSK) position steady in Q2 2018 at 11,356 shares worth $572K. The position accounts for 0.13% of the portfolio, ranked #123.

Catawba Capital Management first reported a position in GSK in Q2 2013 and has held it in 21 quarters since. The position peaked at $1.19M in Q2 2014. 787 funds tracked by Wall St. Rank hold GSK as of Q2 2018.

Catawba Capital Management held 11,356 shares of GSK worth $572K as of Q2 2018.
Catawba Capital Management left its GSK share count unchanged in Q2 2018.
GSK made up 0.13% of Catawba Capital Management's portfolio in Q2 2018, its #123 holding.
Catawba Capital Management first reported a position in GSK in Q2 2013 and has held it in 21 quarters since.
Catawba Capital Management's GSK position peaked at $1.19M in Q2 2014.
787 funds tracked by Wall St. Rank held GSK as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.